IN THE CLAIMS

Please amend the claims as follows:

- 1. (Currently Amended) A capsule system for oral delivery of an active agent—having—a low—aqueous solubility, said capsule system comprising:
- an active retinoid agent—having low aqueous solubility;
- \underline{a} vehicle $\underline{\text{means}}$ —for initially dissolving the active agent;
- <u>an</u> emulsifier <u>means</u> for promoting selfemulsification of the active agent and vehicle <u>means</u> in the gastrointestinal tract; and
- a capsule shell means—for encapsulating the active agent, vehicle—means, and emulsifier means—as a non-emulsified, homogeneous mixture, said capsule shell means being formulated to open upon ingestion into said gastrointestinal tract and release the active agent and vehicle—means—mixture, thus enabling self-emulsification of the vehicle—means, with the active agent dissolved therein in the gastrointestinal tract.
- 2. (Currently Amended) The capsule system according to claim 1 wherein said vehicle means—comprises a liquid medium chain triglyceride fully dissolving said active retinoid agent.
- 3. (Original) The capsule system according to claim 2 wherein said liquid medium chain triglyceride comprises caprylic/capric triglyceride.
- 4. (Currently Amended) The capsule system according to claim 2 wherein said vehicle means—is selected from a group consisting of: Ethyl oleate, Isopropyl myristrate,

Cetearyl octanoate, Corn oil, Cottonseed oil, Safflower oil, Olive oil, Peanut oil, Soybean oil, and Sesame oil.

- 5. (Currently Amended) The capsule system according to claim 3 wherein said emulsifier means—comprises coemulsifiers.
- 6. (Original) The capsule system according to claim 5 wherein said coemulsifiers comprise Sorbitan Monooleate and Polysorbate 80.
- 7. (Original) The capsule system according to claim 5 wherein the coemulsifiers are selected from the group consisting of: Sorbitan monooleate, Sorbitan monolaurate, Sorbitan monopalmitate, Sorbitan monostearate, Polysorbate 20, Polysorbate 40, Polysorbate 60 and Polysorbate 80.
- 8. (Original) The capsule system according to claim 7 wherein said coemulsifiers are selected to match a hydrophilic/lipophilic balance of the caprylic/capric triglyceride.

9. (Cancelled)

- 10. (Currently Amended) The capsule system according to claim 9—8 further comprising an antioxidant present in said vehicle—means.
- 11. (Currently Amended) The capsule system according to claim 10 wherein said capsule shell means—further comprises an opaque colorant.
- 12. (Currently Amended) The capsule system according to claim 11 wherein the Tazarotene—active agent is present in the amount of up to about 34 mg/capsule, the antioxidant comprises butylated hydroxyanisole in the amount of about

- 0.05% w/w, the sorbitan monooleate is present in the amount of about 5.0% w/w, the polysorbate 80 is present in the amount of about 0.25% w/w and the caprylic/capric triglyceride is present in the amount of about 94% w/w.
- 13. (Currently Amended) A capsule system for oral delivery of an active agent—having low aqueous solubility, said capsule system comprising:

an active retinoid agent having low aqueous solubility;

a liquid triglyceride fully dissolving said
active agent;

an emulsifier means for promoting selfemulsification of the liquid triglyceride and dissolved
active agent in a gastrointestinal tract; and

capsule shell means—for encapsulating the liquid triglyceride with dissolved active agent and emulsifier means—as a non-emulsified, homogeneous mixture, said capsule shell means—being formulated to open upon ingestion into said gastrointestinal tract and release the mixture, thus enabling self-emulsification of the liquid triglyceride and dissolved active agent in the gastrointestinal tract.

- 14. (Original) The capsule system according to claim 13 wherein said liquid triglyceride comprises caprylic/capric triglyceride.
- 15. (Currently Amended) The capsule system according to claim 14 wherein said liquid triglycerideemulsifier comprises coemulsifiers.

- 16. (Original) The capsule system according to claim 15 wherein said coemulsifiers comprise Sorbitan Monooleate and polysorbate 80.
- 17. (Original) The capsule system according to claim 15 wherein said coemulsifiers are selected to match a hydrophilic/lipophilic balance of the caprylic/capric triglyceride.
- 18. (Original) The composition comprising the active agent liquid triglyceride, coemulsifiers and emulsifier means—of claim 17.

19. (Cancelled)

- 20. (Currently Amended) The capsule system according to claim 19—18 further comprising an antioxidant present in said vehicle—means.
- 21. (Currently Amended) The capsule system according to claim 20 wherein said capsule shell means—further comprises an opaque colorant.
- 22. (Currently Amended) The capsule system according to claim 21 wherein the Tazarotene active agent is present in the amount of between about 0.1 mg/capsule and about 34 mg/capsule, the antioxidant comprises butylated hydroxyanisole into an amount of about 0.05% w/w, the sorbitan monooleate is present in the amount of about 5.0% w/w capsule, the polysorbate 80 is present in the amount of about 0.25% w/w and the caprylic/capric triglyceride is present in the amount of about 94% w/w.

Claims 23-27 cancelled.